亨迪药业 (301211.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

52.4x

Market Cap

CNY 4.91B

MomentumView details →

1D Return

−5.77%

YTD Return

−5.07%

RSI (14)

46.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

52.4x

Market Cap

CNY 4.91B

RSI (14)

46.2

MomentumView details →

1D Return

−5.77%

YTD Return

−5.07%

ProfitabilityView details →

Gross Margin

21.78%

Net Margin

7.36%

EBITDA Margin

18.37%

ROE (TTM)

1.48%

ROA (TTM)

1.41%

Asset Turnover

0.19x

GrowthView details →

Revenue YoY

+8.71%

EPS YoY

−54.29%

FCF YoY

+0.98%

Revenue CAGR 3Y

−4.16%

EPS CAGR 3Y

−43.35%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

17.18x

Quick Ratio

15.97x

Div Yield

0.52%

Div Rate

CNY 0.06

Div Growth 1Y

−65.20%

Financials snapshotView financials →

Revenue (TTM)

459.02M

Net Income (TTM)

33.80M

Op. CF (TTM)

−968976.30

Latest newsMore news →

Hendi Pharmaceutical announced its 2026 half-year results: net profit attributable to shareholders was 30.1361 million yuan, up 62.48% year-on-year.12d ago

Similar companies

长虹华意000404.SZ 泰和科技300801.SZ 信通电子001388.SZ 安科瑞300286.SZ 莱茵生物002166.SZ 金洲管道002443.SZ Find similar companies →

Latest newsMore news →

Hendi Pharmaceutical announced its 2026 half-year results: net profit attributable to shareholders was 30.1361 million yuan, up 62.48% year-on-year.12d ago